OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Up 441.2% in September

OSR Holdings, Inc. (NASDAQ:OSRH) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 528,200 shares, a growth of 441.2% from the September 15th total of 97,600 shares. Based on an average daily volume of 5,020,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 7.6% of the shares of the company are short sold. Approximately 7.6% of the shares of the company are short sold. Based on an average daily volume of 5,020,000 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

OSRH has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of OSR in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of OSR to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, OSR currently has an average rating of “Sell”.

OSR Trading Up 2.7%

NASDAQ:OSRH opened at $0.58 on Friday. OSR has a 1-year low of $0.45 and a 1-year high of $13.40. The company’s fifty day moving average price is $0.63 and its 200-day moving average price is $1.05.

OSR (NASDAQ:OSRH) last announced its quarterly earnings results on Thursday, August 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $1.14 million for the quarter.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.